Baiyi Medical Completes Tens of Millions RMB Series A Strategic Financing to Advance Thyroid Disease Management Innovation

Recently, Shanghai Baiyi Medical Technology Co., Ltd. (referred to as: Baiyi Medical) completed a strategic financing of tens of millions of RMB in its Series A round. The participating institutions in this round of financing included Zhongshan Cuiheng Venture Capital and Hongrun Private Equity Fund.

The funds from this round of financing will be mainly used for the promotion of the company's first self-developed automatic ophthalmic measuring instrument in the Chinese market, post-marketing research, and European CE registration. At the same time, it will further enrich the company’s product portfolio in the field of thyroid-related diseases, accelerate the process of making high-end innovative medical devices produced in China accessible throughout the country, and provide strong support for Shanghai Baiyi Medical Technology Co., Ltd. to achieve its internationalization strategy.

Shanghai Baiyi Medical Technology Co., Ltd. was founded in 2020 and is located in Zhangjiang, Shanghai. It is an innovative medical device company focusing on the field of thyroid single disease. The company’s strategic core is to create first-in-class (FIC) and best-in-class (BIC) products that fill clinical gaps globally. It is committed to establishing an international standard system for the full-course management of thyroid diseases, filling the international gap in this field.

Shanghai Baiyi Medical Technology Co., Ltd.'s core product, the "Automatic Ophthalmic Measurement Device," has obtained the Class II medical device registration certificate from the National Medical Products Administration (NMPA). This marks the product's official entry into the industrialization channel as the "gold standard" for thyroid eye disease diagnosis. The product has not only been awarded the world’s first innovative medical device certification specifically for evaluating the severity of thyroid eye disease but has also successfully been included in Shanghai's "New and Excellent Medical Device Catalog." Within just four months of its market launch, it has rapidly been adopted by 25 top-tier tertiary hospitals across China, gaining significant clinical recognition.

On this basis, Shanghai Baiyi Medical Technology Co., Ltd. further deepens clinical translational cooperation and international exchanges. The company collaborates extensively with multiple clinical research centers, focusing on transforming frontline clinical needs into cutting-edge technological solutions, thereby establishing a closed-loop R&D system of "clinical needs - technological innovation - application validation."

At the same time, as the only innovative medical device company invited from China, the company successively appeared at the European International Forum on Thyroid Eye Disease and the Cambridge London Technology Forum in the UK, showcasing China's innovative strength in the field of life sciences to the world. It has not only emerged in the Chinese market but also gained widespread attention from the international community, achieving a strategic leap from "Chinese innovation" to "global recognition."

Du Dong, Chairman of Shanghai Baiyi Medical Technology Co., Ltd., on securing this round of financingStated: "We are very grateful to the two industry investors, Zhongshan Cuiheng Venture Capital and Hongrun Private Equity Fund, for their recognition of Baiyi Medical. This round of financing is the company's first step towards commercialization and internationalization. We hope that with the accelerated promotion of this round of financing, we will take innovation as the engine, technology as the driver, clinical needs as the foundation, and clinical value as the orientation, further filling the gap in China's global innovative transformation in the field of thyroid-related diseases."

Zhongshan Cuiheng Venture CapitalIndicates: The thyroid disease management track where Shanghai Baiyi Medical Technology Co., Ltd. is located is entering a golden period of pharmaceutical-device synergy. On one hand, the rising detection rate of diseases has spurred treatment demand; for instance, 40% of Graves' disease patients develop Thyroid Eye Disease (TED). Such patients require precise diagnostic equipment to assess their condition and formulate drug regimens, creating a "diagnosis-guided treatment" interaction. On the other hand, industrial transformation and policy support pave the way for pharmaceutical-device innovation. By 2030, China’s TED drug market and the international TED drug market are projected to reach 450 million USD and 3 billion USD, respectively. This vast demand, in turn, drives the application of diagnostic devices, which serve as tools for pre-medication screening and treatment monitoring, ensuring drug efficacy while optimizing treatment plans, highlighting the closed-loop value of "treatment feeding back into diagnosis."

Hongrun CapitalShanghai Baiyi Medical Technology Co., Ltd. deeply explores the clinical needs of thyroid single disease, breaks through the barriers between basic research and clinical practice, and achieves innovative breakthroughs in translational medicine for thyroid disease solutions. The company’s products under development are pioneering, with a product pipeline that covers integrated diagnostic and therapeutic services in the endocrine field from early screening to diagnosis and postoperative recovery, all of which are essential clinical products. It is believed that, with the support of the industrial ecosystem in Taicang Port Area, Shanghai Baiyi Medical Technology Co., Ltd. will achieve even greater success.